Arketamine for cognitive impairment in psychiatric disorders

• Published in: European archives of psychiatry and clinical neuroscience Vol. 273; no. 7; pp. 1513 - 1525
• Main Author: Hashimoto, Kenji
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.10.2023; Springer; Springer Nature B.V
• Subjects: Antidepressants; Aspartate; Bipolar disorder; Cognitive ability; Glutamic acid receptors; Health aspects; Immune response; Immunosuppressive agents; Invited Review; Ketamine; Medicine; Medicine & Public Health; Mental depression; Mental disorders; Methyl aspartate; Microbiomes; N-Methyl-D-aspartic acid receptors; Neurosciences; Phencyclidine; Psychiatry; Psychosis; Schizophrenia; Esketamine; Gut microbiota; Cognition; Ketamine; Arketamine

Cognitive impairment has been observed in patients with various psychiatric disorders, including schizophrenia, major depressive disorder (MDD), and bipolar disorder (BD). Although modern therapeutic drugs can improve certain symptoms (i.e., psychosis, depression) in these patients, these drugs have...